• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[骨与关节疾病的流行病学——现状与未来——。骨质疏松症医学筛查系统的现状与问题]

[Epidemiology of bone and joint disease - the present and future - . The present situation and problems associated with medical screening systems for osteoporosis].

作者信息

Nakatoh Shinichi

机构信息

Department of Orthopaedic Surgery, Asahi General Hospital, Japan.

出版信息

Clin Calcium. 2014 May;24(5):719-26.

PMID:24769683
Abstract

The current low osteoporosis treatment rate (20%) in Japan is problematic. Osteoporosis screening is needed to ensure that asymptomatic osteoporosis patients are identified and treated. However, five problems are associated with osteoporosis screening in Japan. First, among 1,783 district municipalities, osteoporosis screening was performed in only 1,062 municipalities in 2011. The performance rate is approximately 60% every year. Often, screening was not performed because of financial reasons. Second, the screening participation rates are low and vary among districts (0 - 15%). Third, the bone mineral density measuring apparatus is not sufficiently and widely available for osteoporosis screening. Fourth, the screening results are mainly determined from bone mineral densities; therefore, fracture risk factors besides bone mineral density are not sufficiently reflected in the results. Finally, the screening interval is 5 years, which appears to be excessively longer than the interval of cancer screening. The Fracture Risk Assessment Tool (FRAX(®)) and locomotion check are useful methods for solving these problems. The addition of these two tools to the specific health check-ups increased the participation of patients from Asahi-machi compared with that previously observed ; the use of these tools was inexpensive. Furthermore, education and enlightenment regarding osteoporosis are important to increase the osteoporosis medical treatment rate and to spread awareness regarding osteoporosis screening through osteoporosis liaison services.

摘要

日本目前较低的骨质疏松症治疗率(20%)存在问题。需要进行骨质疏松症筛查,以确保识别并治疗无症状的骨质疏松症患者。然而,日本的骨质疏松症筛查存在五个问题。首先,在1783个地区市町村中,2011年只有1062个市町村开展了骨质疏松症筛查。每年的执行率约为60%。筛查常常因经济原因而未进行。其次,筛查参与率较低,且各地区有所不同(0 - 15%)。第三,骨密度测量设备在骨质疏松症筛查方面的供应不足且不够广泛。第四,筛查结果主要由骨密度决定;因此,除骨密度外的骨折风险因素在结果中未得到充分体现。最后,筛查间隔为5年,这似乎比癌症筛查间隔长得过多。骨折风险评估工具(FRAX(®))和运动检查是解决这些问题的有效方法。将这两种工具添加到特定健康检查中,与之前相比,旭町患者的参与度有所提高;使用这些工具成本较低。此外,关于骨质疏松症的教育和宣传对于提高骨质疏松症医疗治疗率以及通过骨质疏松症联络服务普及骨质疏松症筛查意识很重要。

相似文献

1
[Epidemiology of bone and joint disease - the present and future - . The present situation and problems associated with medical screening systems for osteoporosis].[骨与关节疾病的流行病学——现状与未来——。骨质疏松症医学筛查系统的现状与问题]
Clin Calcium. 2014 May;24(5):719-26.
2
Application of the fracture risk assessment tool (FRAX(®)) and determination of suitable cut-off values during primary screening in specific health check-ups in Japan.在日本的特定健康检查中,应用骨折风险评估工具(FRAX(®))并确定合适的截断值进行初步筛查。
J Bone Miner Metab. 2013 Nov;31(6):674-80. doi: 10.1007/s00774-013-0457-6. Epub 2013 Mar 30.
3
FRAX without bone mineral density versus osteoporosis self-assessment screening tool as predictors of osteoporosis in primary screening of individuals aged 70 and older.不基于骨密度的 FRAX 与骨质疏松症自我评估筛查工具在 70 岁及以上人群的初筛中预测骨质疏松症的比较。
J Am Geriatr Soc. 2014 Mar;62(3):442-6. doi: 10.1111/jgs.12696. Epub 2014 Mar 11.
4
[Primary fracture prevention through the Osteoporosis Liaison Service.].通过骨质疏松症联络服务进行原发性骨折预防。
Clin Calcium. 2017;27(9):1233-1240.
5
[Epidemiology of bone and joint disease - the present and future - . Epidemiology of osteoporosis and osteoporotic fracture in Japan].[骨与关节疾病的流行病学——现状与未来——。日本骨质疏松症及骨质疏松性骨折的流行病学]
Clin Calcium. 2014 May;24(5):657-64.
6
[Clinical application of FRAX® in Japan].FRAX®在日本的临床应用
Clin Calcium. 2012 Jun;22(6):857-63.
7
Assessment of fracture risk: who should be treated for osteoporosis?骨折风险评估:哪些人应该接受骨质疏松症治疗?
Best Pract Res Clin Rheumatol. 2005 Dec;19(6):937-50. doi: 10.1016/j.berh.2005.06.001.
8
Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.美国成年人群骨质疏松症筛查:美国预防医学学院关于预防实践的立场声明。
Am J Prev Med. 2009 Apr;36(4):366-75. doi: 10.1016/j.amepre.2009.01.013.
9
Bone density, bone quality, and FRAX: changing concepts in osteoporosis management.骨密度、骨质量和 FRAX:骨质疏松症管理中的新概念。
Am J Obstet Gynecol. 2013 Feb;208(2):92-6. doi: 10.1016/j.ajog.2012.10.874. Epub 2012 Oct 23.
10
[Utility and problems of FRAX in clinical use].[FRAX在临床应用中的效用与问题]
Clin Calcium. 2009 Dec;19(12):1756-67.

引用本文的文献

1
A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.基于模型的绝经后日本女性骨质疏松症筛查和治疗策略的成本效益分析。
Osteoporos Int. 2017 Feb;28(2):643-652. doi: 10.1007/s00198-016-3782-5. Epub 2016 Oct 14.